Gilead rescues biopharma’s takeout scene
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Bristol bets big on Myokardia
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
More biotechs test the third way to market
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
For a quick exit, head to the stock market
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
